AK 104

Drug Profile

AK 104

Alternative Names: AK104

Latest Information Update: 07 Dec 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Akesobio Australia
  • Class Antineoplastics; Bispecific antibodies
  • Mechanism of Action Programmed cell death-1 receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase I Solid tumours

Most Recent Events

  • 03 Oct 2017 Phase-I clinical trials in Solid tumours (Late-stage disease, Metastatic disease, Second-line therapy or greater) in Australia (IV) (NCT03261011)
  • 20 Aug 2017 Akesobio Australia plans a phase I trial for Solid tumours (Late-stage disease, Metastatic disease, Second-line therapy or greater) in Australia (IV) (NCT03261011)
  • 20 Aug 2017 Preclinical trials in Solid tumours (Late-stage disease) in Australia (IV) before August 2017 (NCT03261011)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top